## Abstract Although tamoxifen (TAM) is used for the frontβline treatment and prevention of estrogen receptorβpositive (ER+) breast tumors, nearly 40% of estrogenβdependent breast tumors do not respond to TAM treatment. Moreover, the positive response is usually of short duration, and most tumors e
Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells
β Scribed by Surojeet Sengupta; Rachel Schiff; Benita S. Katzenellenbogen
- Publisher
- Springer US
- Year
- 2008
- Tongue
- English
- Weight
- 434 KB
- Volume
- 117
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Four and a half LIM domain protein 2 (FHL2) has been implicated in development and progression of various types of cancers. However, little is known about the biological function of FHL2 in breast cancer. Here, we report that FHL2 physically and functionally interacts with estrogen rece
Background. Influence of tamoxifen treatment on estrogen receptor (ER) and progesterone receptor (PR) levels in human breast cancer has not been fully elucidated in vivo. This problem was studied in 20 postmenopausal patients with ER-positive and PR-positive primary breast cancer. Each patient unde
## Abstract The cyclinβdependent kinase inhibitor protein p21^Waf1/Cip1^ is a potent tumor suppressor. Here, we demonstrate that estradiol regulates the p21^Waf1/Cip1^ gene. Estradiol induces p21^Waf1/Cip1^ mRNA expression within 30β60βmin independent of new protein synthesis in the estrogen recept